-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche Launches Global VENTANA BAP1 (SP527) Test To Distinguish Malignant Mesothelioma From Lung, Breast, Stomach Cancers, Expanding Cancer Diagnostic Portfolio

Benzinga·10/28/2026 06:28:04
Diffusion vocale
  • The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen.
  • Most patients are diagnosed with mesothelioma late, resulting in a median overall survival of just 12 to 18 months.1
  • Roche's comprehensive cancer diagnostic portfolio delivers end-to-end clinical answers across the patient journey, spanning advanced tissue diagnostics, core lab immunoassays, molecular testing and digital diagnostics.